These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17698833)

  • 1. Genetic analysis to prevent warfarin complications.
    Lippi G; Salvagno GL; Guidi GC
    CMAJ; 2007 Aug; 177(4):377. PubMed ID: 17698833
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetics of warfarin response.
    Mannucci PM; Spreafico M; Peyvandi F
    N Engl J Med; 2008 Jun; 358(25):2743; author reply 2743-4. PubMed ID: 18572453
    [No Abstract]   [Full Text] [Related]  

  • 3. Genetics of warfarin response.
    Kulkarni UP; Karnad DR; Gogtay NJ
    N Engl J Med; 2008 Jun; 358(25):2742-3; author reply 2743-4. PubMed ID: 18572454
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetics of warfarin response.
    Neville KA; Wicklund BM; Kearns GL
    N Engl J Med; 2008 Jun; 358(25):2742. PubMed ID: 18572452
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacogenomics--ready for prime time?
    Shurin SB; Nabel EG
    N Engl J Med; 2008 Mar; 358(10):1061-3. PubMed ID: 18322288
    [No Abstract]   [Full Text] [Related]  

  • 6. The pharmacogenomics of warfarin (Coumadin) administration.
    Ruano G; Bower B
    Conn Med; 2006 Apr; 70(4):251-2. PubMed ID: 16768072
    [No Abstract]   [Full Text] [Related]  

  • 7. Genetic help for a blood-thinner balancing act? There's little evidence yet that a genetic test improves the safety of warfarin.
    Harv Heart Lett; 2007 Dec; 18(4):1-2. PubMed ID: 18219801
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetic testing for warfarin dosing? Not yet ready for prime time.
    Bussey HI; Wittkowsky AK; Hylek EM; Walker MB
    Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants.
    Schwarz UI; Stein CM
    Clin Pharmacol Ther; 2006 Jul; 80(1):7-12. PubMed ID: 16815312
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacogenetic-based dosing of warfarin.
    Med Lett Drugs Ther; 2008 May; 50(1286):39-40. PubMed ID: 18487958
    [No Abstract]   [Full Text] [Related]  

  • 11. Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin.
    Siguret V; Pautas E; Gouin-Thibault I
    Vitam Horm; 2008; 78():247-64. PubMed ID: 18374198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].
    Loriot MA; Beaune P
    Rev Med Interne; 2006 Dec; 27(12):979-82. PubMed ID: 17070618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Warfarin monitoring woes: a glimmer of hope with pharmacogenomics.
    Beier MT
    J Am Med Dir Assoc; 2008 Mar; 9(3):199-200. PubMed ID: 18294604
    [No Abstract]   [Full Text] [Related]  

  • 14. Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen.
    Sconce EA; Kamali F
    Eur J Haematol; 2006 Dec; 77(6):457-62. PubMed ID: 17042764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes.
    Fukuda T; Tanabe T; Ohno M; Tougou K; Fujio Y; Azuma J; Yamamoto I; Takeda A
    Clin Pharmacol Ther; 2006 Nov; 80(5):553-4. PubMed ID: 17112813
    [No Abstract]   [Full Text] [Related]  

  • 16. VKORC1: a warfarin-sensitive enzyme in vitamin K metabolism and biosynthesis of vitamin K-dependent blood coagulation factors.
    Wallin R; Wajih N; Hutson SM
    Vitam Horm; 2008; 78():227-46. PubMed ID: 18374197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new VKORC1 mutation leading to an isolated resistance to fluindione.
    Peoc'h K; Pruvot S; Gourmel C; dit Sollier CB; Drouet L
    Br J Haematol; 2009 Jun; 145(6):841-3. PubMed ID: 19344422
    [No Abstract]   [Full Text] [Related]  

  • 18. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmocogenomics of warfarin: closing in on personalized medicine.
    Rettie AE; Tai G
    Mol Interv; 2006 Aug; 6(4):223-7. PubMed ID: 16960144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of warfarin: current status and future challenges.
    Wadelius M; Pirmohamed M
    Pharmacogenomics J; 2007 Apr; 7(2):99-111. PubMed ID: 16983400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.